Laboratory Medicine ›› 2018, Vol. 33 ›› Issue (9): 868-871.DOI: 10.3969/j.issn.1673-8640.2018.09.023
Previous Articles Next Articles
Received:2018-01-02
Online:2018-09-30
Published:2018-10-13
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2018.09.023
| 抗体 | 荧光表达（%） | 阳性/阴性 |
|---|---|---|
| CD2 | 0.9 | 阴性 |
| CD1a | 0.0 | 阴性 |
| CD4 | 0.6 | 阴性 |
| CD8 | 0.5 | 阴性 |
| CD3 | 0.4 | 阴性 |
| CD5 | 3.6 | 阴性 |
| CD10 | 0.5 | 阴性 |
| CD15 | 37.5 | 阳性 |
| CD16 | 7.3 | 阴性 |
| CD58 | 67.2 | 阳性 |
| CD33 | 85.7 | 阳性 |
| CD123 | 36.2 | 阳性 |
| cCD3 | 40.0 | 阳性 |
| cCD79 | 2.3 | 阴性 |
| CD7 | 89.1 | 阳性 |
| CD56 | 0.5 | 阴性 |
| CD34 | 95.5 | 阳性 |
| CD19 | 0.6 | 阴性 |
| CD38 | 66.2 | 阳性 |
| HLA-DR | 0.8 | 阴性 |
| CD11b | 65.4 | 阳性 |
| CD14 | 0.1 | 阴性 |
| 抗体 | 荧光表达（%） | 阳性/阴性 |
|---|---|---|
| CD2 | 0.9 | 阴性 |
| CD1a | 0.0 | 阴性 |
| CD4 | 0.6 | 阴性 |
| CD8 | 0.5 | 阴性 |
| CD3 | 0.4 | 阴性 |
| CD5 | 3.6 | 阴性 |
| CD10 | 0.5 | 阴性 |
| CD15 | 37.5 | 阳性 |
| CD16 | 7.3 | 阴性 |
| CD58 | 67.2 | 阳性 |
| CD33 | 85.7 | 阳性 |
| CD123 | 36.2 | 阳性 |
| cCD3 | 40.0 | 阳性 |
| cCD79 | 2.3 | 阴性 |
| CD7 | 89.1 | 阳性 |
| CD56 | 0.5 | 阴性 |
| CD34 | 95.5 | 阳性 |
| CD19 | 0.6 | 阴性 |
| CD38 | 66.2 | 阳性 |
| HLA-DR | 0.8 | 阴性 |
| CD11b | 65.4 | 阳性 |
| CD14 | 0.1 | 阴性 |
| [1] | HAYDU J E,FERRANDO A A.Early T-cell precursor acute lymphoblastic leukaemia[J]. Curr Opin Hematol,2013,20(4):369-373. |
| [2] | COUSTAN-SMITH E,MULLIGHAN C G,ONCIU M,et al.Early T-cell precursor leukaemia:a subtype of very high-risk acute lymphoblastic leukaemia[J]. Lancet Oncol,2009,10(2):147-156. |
| [3] | ZHANG J,DING L,HOLMFELDT L,et al.The genetic basis of early T-cell precursor acute lymphoblastic leukaemia[J]. Nature,2012,481(7380):157-163. |
| [4] | 克晓燕,高子芬. 淋巴瘤诊疗手册[M]. 2版. 北京:人民卫生出版社,2017:100-101. |
| [5] | MOK M M,DU L,WANG C Q,et al.RUNX1 point mutations potentially identify a subset of early immature T-cell acute lymphoblastic leukaemia that may originate from differentiated T-cells[J]. Gene, 2014,545(1):111-116. |
| [6] | CHOPRA A,BAKHSHI S,PRAMANIK S K,et al.Immunophenotypic analysis of T-acute lymphoblastic leukemia. A CD5-based ETP-ALL perspective of non-ETP T-ALL[J]. Eur J Haematol,2014,92(3):211-218. |
| [7] | NEUMANN M,COSKUN E,FRANSECKY L,et al.FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors[J]. PLoS One,2013,8(1): e53190. |
| [8] | 高举,陈晓曦. 儿童急性T淋巴细胞白血病诊治进展[J]. 中国小儿血液与肿瘤杂志,2013,18(4):148-152. |
| [9] | INUKAI T,KIYOKAWA N,CAMPANA D,et al.Clinical significance of early T-cell precursor acute lymphoblastic leukaemia:results of the Tokyo Children's Cancer Study Group Study L99-15[J]. Br J Haematol,2012,156(3):358-365. |
| [10] | PUI C H,MULLIGHAN C G,EVANS W E,et al.Pediatric acute lymphoblastic leukemia:where are we going and how do we get there?[J]. Blood,2012,120(6):1165-1174. |
| [11] | 中国抗癌协会血液肿瘤专业委员会,中华医学会血液学分会白血病淋巴瘤学组. 中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版)[J]. 中华血液学杂志,2016,37(10):837-845. |
| [12] | MA M,WANG X,TANG J,et al.Early T-cell precursor leukemia:a subtype of high risk childhood acute lymphoblastic leukemia[J]. Front Med,2012,6(4):416-420. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
